Silo Pharma (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases to be made on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. As of November 13, 2025, the company reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended September 30, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This move is often interpreted as a signal that management believes the stock is undervalued and can provide support to the share price.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The share repurchase authorization comes at a time when the company is advancing its pipeline. For more details, the full press release is available at https://ibn.fm/gU3uZ. Investors can find the latest news and updates on SILO in the company's newsroom at https://ibn.fm/SILO.
This announcement is important as it reflects the board's confidence in Silo Pharma's financial health and future prospects. Share repurchase programs can enhance shareholder value by reducing the number of outstanding shares, potentially increasing earnings per share. However, the program's effectiveness will depend on market conditions and the company's execution.
